GSK3A and melanoma: LY2090314, a selective small-molecule inhibitor of GSK3α/β, stabilized β-catenin and stimulated the expression of AXIN2 in A375 melanoma cells, causing a tumor growth delay in vivo both as a single agent and in combination with dacarbazine (DTIC), and induced apoptotic cell death in melanoma cell lines irrespective of the BRAF mutation status [104].